Incidence of Severe COVID-19 Infection in Patients With CLL or B-NHL Who Received Pre-exposure Prophylaxis With Tixagevimab and Cilgavimab in Italy.

RecruitingOBSERVATIONAL
Enrollment

954

Participants

Timeline

Start Date

September 12, 2023

Primary Completion Date

September 30, 2024

Study Completion Date

September 30, 2024

Conditions
Chronic Lymphocytic LeukemiaIndolent B-Cell Non-Hodgkin LymphomaCOVID-19
Trial Locations (15)

Unknown

RECRUITING

UOC Ematologia AO Cosenza, Cosenza

RECRUITING

Ematologia AOU S.Anna, Ferrara

RECRUITING

Ematologia AOU Careggi, Florence

RECRUITING

ASST Lecco Ospedale A.Manzoni, Lecco

RECRUITING

UOC Ematologia ATMO, Livorno

RECRUITING

ASST Grande Ospedale Metropolitano Niguarda, Milan

RECRUITING

SCDU Ematologia, Novara

RECRUITING

Dipartimento Oncologico La Maddalena, Palermo

RECRUITING

UOC DI ONCOEMATOLOGIA AOR Villa Sofia - Cervello, Palermo

RECRUITING

"Ematologia Università Sapienza Roma", Roma

RECRUITING

IRCCS Istituto Clinico Humanitas, Rozzano

RECRUITING

UOC Ematologia Casa Sollievo della Sofferenza, San Giovanni Rotondo

RECRUITING

SCDU Ematologia e terapie cellulari AO Mauriziano, Torino

RECRUITING

Ematologia Ospedale S.Chiara, Trento

RECRUITING

UOC ematologia ULSS2 Marca Trevigiana, Treviso

All Listed Sponsors
collaborator

Fondazione Italiana Linfomi

UNKNOWN

lead

Gruppo Italiano Malattie EMatologiche dell'Adulto

OTHER